M
Min Gao
Researcher at Bristol-Myers Squibb
Publications - 78
Citations - 5614
Min Gao is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Hepatitis C virus & NS5A. The author has an hindex of 35, co-authored 73 publications receiving 5312 citations.
Papers
More filters
Journal ArticleDOI
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
Mark S. Sulkowski,David F. Gardiner,Maribel Rodriguez-Torres,K. Rajender Reddy,Tarek Hassanein,Ira M. Jacobson,Eric Lawitz,Anna S. Lok,Federico Hinestrosa,Paul J. Thuluvath,Howard J. Schwartz,David R. Nelson,Gregory T. Everson,Timothy Eley,Megan Wind-Rotolo,Shu-Pang Huang,Min Gao,Dennis Hernandez,Fiona McPhee,Diane Sherman,R. Hindes,William T. Symonds,Claudio Pasquinelli,Dennis M. Grasela +23 more
TL;DR: Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.
Journal ArticleDOI
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao,Richard E. Nettles,Makonen Belema,Lawrence B. Snyder,Van N. Nguyen,Robert A. Fridell,Michael H. Serrano-Wu,David R. Langley,Jin-Hua Sun,Donald R. O'Boyle,Julie A. Lemm,Chunfu Wang,Jay O. Knipe,Caly Chien,Richard J. Colonno,Dennis M. Grasela,Nicholas A. Meanwell,Lawrence G. Hamann +17 more
TL;DR: These results provide the first clinical validation of an inhibitor of HCV NS5A, a protein with no known enzymatic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations ofHCV inhibitors.
Journal ArticleDOI
Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System
TL;DR: As an initial step toward correlating in vitro and in vivo resistances, multiple cell lines and selective pressures were used to identify BMS-790052-resistant variants in genotype 1 replicons, suggesting that multiple mutations will likely be required for significant in vivo resistance in this genetic background.
Journal ArticleDOI
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS‐790052 in Humans: In Vitro and In Vivo Correlations
Robert A. Fridell,Chunfu Wang,Jin-Hua Sun,Donald R. O'Boyle,Peter T. Nower,Lourdes Valera,Dike Qiu,Susan B. Roberts,Xin Huang,Bernadette Kienzle,Marc Bifano,Richard E. Nettles,Min Gao +12 more
TL;DR: Although resistance emerged during monotherapy with BMS‐790052, the substantial anti‐HCV effect of this compound makes it an excellent candidate for effective combination therapy.
Journal ArticleDOI
The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth.
Min Gao,L. Matusick-Kumar,W. Hurlburt,S F DiTusa,W. W. Newcomb,Jay C. Brown,P.J. McCann rd,Ingrid C. Deckman,Richard J. Colonno +8 more
TL;DR: The herpes simplex virus type 1 protease and related proteins are involved in the assembly of viral capsids and the function of Na, at least in part, is to direct the catalytic domain N(o) to the nucleus.